What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Clear Cell Renal Cell Carcinoma, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
- Main trialPhase 1/2
- “This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.”In the company’s words, NCT07097935 on ClinicalTrials.gov
Other drugs for Advanced Clear Cell Renal Cell Carcinoma
- BCD-217Biocad · Phase 3
- ProlgolimabBiocad · Phase 3
- BalstilimabAgenus Inc. · Phase 2
- BotensilimabAgenus Inc. · Phase 2
- SYS6088CSPC · Phase 1/2
- GB268Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2
Coming up1
- 10 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 10 Jul 2027 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | |
| Phase 1Recruiting | 31 Jul 2026 | A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors | |
| Phase 1Unknown | 25 Sep 2024 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026